Search

Media

Welcome to members of the press!

The online press registration for EHA2024 will be open until June 16, 2024.

Read more

Online Case Unit

Current committee members

Marielle Wondergem, The Netherlands (Editor-in-Chief)
Barbara Bain, United Kingdom (Editor)
John Burthem, United Kingdom (Editor)
Mary Frances McMullin, United Kingdom (Editor)
Christopher McNamara, United Kingdom (Editor)

AimThe Online Case Unit guards the quality and consistency of all cases presented at EHA Tutorials and…

Read more

Publications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

New EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect

On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro diagnostic medical devices.

Read more

Precision Hematology

The Precision Hematology Topics-in-Focus program will promote innovative concepts for diagnostics and innovative clinical trial designs, which should translate into the clinical application of precision hematology.

Read more

General Information

June 1, 2024
EHA2024 Congress platform opens

June 13-16, 2024
EHA2024 Madrid, Spain - In-person and live stream

Location 
IFEMA MADRID RECINTO FERIAL (Fairgrounds), Madrid, Spain

August 15, 2024
EHA2024 Congress platform closes

 
 

Scientific Program Committee (SPC) Chair
Prof Brian Huntly

Official Language
English  

EHA Congress Secretariat
INTERPLAN Congress, Meeting & Event Management…

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more